180 related articles for article (PubMed ID: 19843675)
1. Testosterone and biological characteristics of breast cancers in postmenopausal women.
Secreto G; Venturelli E; Meneghini E; Greco M; Ferraris C; Gion M; Zancan M; Fabricio AS; Berrino F; Cavalleri A; Micheli A
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2942-8. PubMed ID: 19843675
[TBL] [Abstract][Full Text] [Related]
2. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study.
Kahán Z; Gardi J; Nyári T; Földesi I; Hajnal-Papp R; Ormándi K; Lázár G; Thurzó L; Schally AV
Int J Oncol; 2006 Jul; 29(1):193-200. PubMed ID: 16773200
[TBL] [Abstract][Full Text] [Related]
3. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women.
Miyoshi Y; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2003 Jun; 9(6):2229-33. PubMed ID: 12796390
[TBL] [Abstract][Full Text] [Related]
4. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
5. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
[TBL] [Abstract][Full Text] [Related]
6. Serum sex hormones and breast cancer risk factors in postmenopausal women.
Lamar CA; Dorgan JF; Longcope C; Stanczyk FZ; Falk RT; Stephenson HE
Cancer Epidemiol Biomarkers Prev; 2003 Apr; 12(4):380-3. PubMed ID: 12692114
[TBL] [Abstract][Full Text] [Related]
7. Circulating steroid hormone levels and risk of breast cancer for postmenopausal women.
Baglietto L; Severi G; English DR; Krishnan K; Hopper JL; McLean C; Morris HA; Tilley WD; Giles GG
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):492-502. PubMed ID: 20086116
[TBL] [Abstract][Full Text] [Related]
8. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.
Grann VR; Troxel AB; Zojwalla NJ; Jacobson JS; Hershman D; Neugut AI
Cancer; 2005 Jun; 103(11):2241-51. PubMed ID: 15844176
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
10. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.
Enger SM; Ross RK; Paganini-Hill A; Carpenter CL; Bernstein L
Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):681-7. PubMed ID: 10919738
[TBL] [Abstract][Full Text] [Related]
11. Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients.
Vandorpe T; Smeets A; Van Calster B; Van Hoorde K; Leunen K; Amant F; Moerman P; Deraedt K; Brouckaert O; Van Huffel S; Wildiers H; Christiaens MR; Neven P
Breast Cancer Res Treat; 2011 Jul; 128(2):429-35. PubMed ID: 21562708
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers associated with breast cancer are associated with obesity.
Sauter ER; Scott S; Hewett J; Kliethermes B; Ruhlen RL; Basarakodu K; de la Torre R
Cancer Detect Prev; 2008; 32(2):149-55. PubMed ID: 18639389
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen value as a marker in breast cancer.
Narita D; Cimpean AM; Anghel A; Raica M
Neoplasma; 2006; 53(2):161-7. PubMed ID: 16575473
[TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes.
Orr RK; Col NF; Kuntz KM
Surgery; 1999 Sep; 126(3):568-76. PubMed ID: 10486611
[TBL] [Abstract][Full Text] [Related]
16. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
17. Plasma prolactin concentrations and risk of postmenopausal breast cancer.
Tworoger SS; Eliassen AH; Rosner B; Sluss P; Hankinson SE
Cancer Res; 2004 Sep; 64(18):6814-9. PubMed ID: 15375001
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
19. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
20. [Proliferation index, axillary lymph node status, hormone receptors and age as prognostic factors in primary breast cancer].
Kaufmann M; Klinga K; Kühn W; Abel U
Geburtshilfe Frauenheilkd; 1989 Feb; 49 Suppl 1():104-8. PubMed ID: 2703135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
